Andere talen Akebia Therapeutics, Inc.

Aandelen

AKBA

US00972D1054

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 12-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,16 ^USD	+4,50%		+2,65%	-6,45%

09/05	Transcript : Akebia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
09/05	Akebia Therapeutics, Inc. rapporteert winstresultaten voor het eerste kwartaal eindigend op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/06
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference	23/05
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference	14/05
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M	09/05
Akebia Therapeutics: Q1 Earnings Snapshot	09/05
Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	09/05
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights	02/05
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/05
Averoa Seeks EU Approval for Chronic Kidney Disease Drug	23/04
Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement	16/04
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	03/04
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/04
Sector Update: Health Care Stocks Advance Premarket Thursday	28/03
Sector Update: Health Care	28/03
Akebia Therapeutics Shares Jump Pre-Bell on FDA Approval of Anemia Treatment for Chronic Kidney Disease Dialysis Patients	28/03
Akebia Shares Rally Premarket After FDA Approves Vafseo	28/03
U.S. FDA approves Akebia's anemia drug	28/03
U.S. FDA approves Akebia's anemia drug	28/03
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis	28/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Akebia Therapeutics, Inc.

Aandelen

AKBA

US00972D1054

Andere talen

Filters